DLinDMA
Formulation & Performance

This edition organizes the previously reviewed, source-linked product record. It is not a new independent review of every paper or supporting file. Reported and calculated values retain their original labels.

View original study figures ↓

Literature-reported formulation composition

Component	mol%	Role
DLin-DMA	50	Ionizable lipid
DSPC	10	Helper phospholipid
Cholesterol	38.5	Sterol
DMG-PEG2000	1.5	PEG lipid
Reported total	100	Source values retained

Component molecular weights and calculated amounts

Composition retained from the cited study below. Research planning aid only. Results cover lipid component weights and do not include RNA, buffer, solvent, process loss or an N/P ratio.

Total lipid mass (mg)

Component	Normalized mol%	Amount (µmol)	Weight (mg)
DLin-DMA	50.000	87.1815	53.7101
DSPC	10.000	17.4363	13.7773
Cholesterol	38.500	67.1297	25.9557
DMG-PEG2000	1.500	2.6154	6.5569

Calculated total: 100.0000 mg lipid.

Calculated catalog planning quantities; RNA, solvent and process loss are excluded. DMG-PEG2000 uses 2507. Component mass = total lipid mass × molar parts × molecular weight / sum(parts × molecular weight). This conversion does not infer N/P.

N/P ratio4

Total lipid:cargo weight ratioNot reported

Buffer & pHFLuc mRNA at 1 mg/mL in 43-50 mM sodium acetate, pH 4; final dialysis against PBS to pH 7.3-7.4.

CargoN1-methylpseudouridine-modified, CleanCap firefly-luciferase mRNA

Administration routeHEK293 cell culture; intramuscular gastrocnemius injection or intravenous retro-orbital injection in separate mouse groups

DoseIn vitro 25, 50, 100 or 200 ng mRNA/well; in vivo 5 micrograms mRNA-LNP/mouse

Animal modelHEK293 cells, 12,000 cells/well; 8-week-old female BALB/c mice

Formulation processLipids were dissolved in ethanol at 50 mM total lipid. A 16 microliter organic phase and 32 microliter aqueous phase were mixed in a Spark NanoAssemblr and ejected into 48 microliters PBS, then diluted with 96 microliters DPBS. LNPs were dialyzed against PBS for 4-6 h with 4-6 buffer exchanges and concentrated for in vivo use.

Literature-reported performance for the cited formulation

Calculated from published source dataIn vitro FLuc reporter signal251-335 RLU at 25 ng; 1543-1920 RLU at 200 ngHEK293, 24 h after transfection, n=3 · Common five-lipid comparison; authors reported KC2 > MC3 > DLin > DODMA > DODAP under these conditionsRange calculated from the three published source-data replicates at each selected dose; intermediate 50 and 100 ng data remain in the source workbook.Main p.5 Fig.3a; Supplementary Data 3, 'Figure 3a'!B3:N7; DLin row B5:N5

Calculated from published source dataIntramuscular FLuc expression61.59-68.35 million photons/s at 4 h; 7.844-15.64 million photons/s at 24 h5 micrograms FLuc mRNA-LNP/mouse, IM; female BALB/c mice · 4 and 24 h · Five ionizable-lipid formulations at the same composition and N/PRanges calculated from published source-data values.Main p.7 Fig.4c; Supplementary Data 4, 'Figure 4c'!B5:H5

Calculated from published source dataIntravenous liver FLuc expression401.8 and 594.7 million photons/s at 4 h; 35.79-190.3 million photons/s at 24 h5 micrograms FLuc mRNA-LNP/mouse, IV; female BALB/c mice · 4 and 24 h · Five ionizable-lipid formulations at the same composition and N/PPublished source-data values; the 4 h sheet contains two DLin values, so no missing third replicate was invented.Main p.7 Fig.4d; Supplementary Data 4, 'Figure 4d'!B5:H5

Published particle and ionization measurements

Parameter	DLin-DMA result	Source
DLS number diameter	62.79 and 69.72 nm	Source Data Fig.3b
PDI	0.246 and 0.249	Source Data Fig.3b
Encapsulation efficiency	72.95% and 74.72%	Source Data Fig.3d
TNS apparent LNP pKa	6.66	Source Data Fig.1d
Zeta-potential pKa / pI	6.15 / 6.34	Source Data Fig.1d
Water-soluble analogue pKa	8.93	Source Data Fig. 1d

Carrasco et al. 2021 main Table 1 and Figs.1,3; Supplementary Data 1 'Figure 1d'!B2:G7 and Supplementary Data 3 'Figure 3b'!B2:F7, 'Figure 3d'!B2:F7

Literature Data DisclaimerAll formulation parameters and performance values shown in this section are derived from the cited publication and are provided for reference only. These results were obtained using the specific materials, formulation process, cargo, dose, analytical method, model and administration route described in that study. Unless otherwise stated, the data were not generated or independently verified by DC Chemicals. DC Chemicals supplies the lipid compound only and does not guarantee that customers will reproduce the reported LNP properties or biological performance.

The administration route shown above was used in the cited study and is not a clinical-use instruction or recommendation by DC Chemicals.

Cited literature for this formulation and performance datasetCarrasco MJ, Alishetty S, Alameh MG, et al. Ionization and structural properties of mRNA lipid nanoparticles influence expression in intramuscular and intravascular administration. Communications Biology. 2021;4:956. DOI: 10.1038/s42003-021-02441-2
The page formulation and all particle/in vivo values use the Carrasco 2021 50:10:38.5:1.5, N/P 4 FLuc mRNA-LNP. Semple 2010 data are separately labelled as a 40 mol% PFV screen with incomplete helper-lipid composition and are not merged with the 2021 formulation.

Published study figures

Original publication figures illustrating the cited formulation and biological results. Select an image to view it at full size.

Figure 3: DLinDMA (labelled DLin) is compared with KC2, MC3, DODMA and DODAP. Luciferase expression and cell viability are shown across mRNA doses; the particle-size and encapsulation measurements refer to the same study formulations. — Figure 3 — Cell expression, viability and LNP characteristics
DLinDMA (labelled DLin) is compared with KC2, MC3, DODMA and DODAP. Luciferase expression and cell viability are shown across mRNA doses; the particle-size and encapsulation measurements refer to the same study formulations. HEK293 cells; FLuc mRNA; N/P 4; 25–200 ng mRNA; 24-hour cell assessment; mean ± SD, n=3.
Carrasco et al. (2021), Communications Biology, Figure 3. CC BY 4.0. Original figure unchanged. Original article / figure · CC BY 4.0. Unmodified complete original figure; displayed at responsive size.

Figure 4: DLinDMA (DLin), MC3, DODMA and DODAP are individually labelled alongside KC2. The relative performance changes between intramuscular and intravenous administration; results should be read within the route and time point shown. — Figure 4 — Route-dependent reporter expression in mice
DLinDMA (DLin), MC3, DODMA and DODAP are individually labelled alongside KC2. The relative performance changes between intramuscular and intravenous administration; results should be read within the route and time point shown. 5 µg FLuc mRNA per mouse; N/P 4; IM or IV; measurements at 4 and 24 hours.
Carrasco et al. (2021), Communications Biology, Figure 4. CC BY 4.0. Original figure unchanged. Original article / figure · CC BY 4.0. Unmodified complete original figure; displayed at responsive size.

DLinDMAFormulation & Performance